Feature | September 05, 2012 | Joost Nuyttens, M.D., Ph.D.

SBRT Treatment for Central Lung Lesions

New research examines the effectiveness of using the CyberKnife system to treat cancer in the difficult central lung area

A CyberKnife treatment plan for lung cancer.

A CyberKnife treatment plan for lung cancer.

The preferred treatment for patients with operable lung cancer is surgical resection. However, many lung cancer patients whose tumors are technically resectable have other medical problems, such as chronic obstructive pulmonary disease, which make it difficult to endure lung cancer surgery. Until the last decade these patients were treated with conventional radiotherapy, but more recently stereotactic body radiotherapy (SBRT), or the accurate delivery of high doses of radiation over a short period of time, has emerged as an alternative treatment.

SBRT has been shown to be effective in the treatment of lesions in the peripheral region of the lungs.[1] Extending SBRT to the central lung is much more complicated. SBRT delivered to lesions located within 2 cm of the primary central airways of the lung can result in pneumonia, pericardial effusion, hemoptysis or even death.[2] Given these risks, it would be understandable if centers shied away from treating patients with central lesions with SBRT.

Observing this trend, and in light of features available with the CyberKnife SBRT system, the Erasmus MC – Daniel den Hoed Cancer Center in Rotterdam launched a study in July 2006 focused specifically on the use of SBRT to treat central lung tumors. The study, "Outcome of Four-Dimensional Stereotactic Radiotherapy for Centrally Located Lung Tumors," reported on 56 patients (39 with primary lung cancer and 17 with metastatic tumors) treated with the CyberKnife system.[3] All of these patients were ineligible for surgery or chemotherapy, refused surgery or chemotherapy, or had an inoperable tumor.

Unlike other SBRT treatment methods, the CyberKnife system is equipped with a technology called the Synchrony respiratory tracking system, making it uniquely suited to treating central lung tumors. The Synchrony system correlates the position of the chest as it rises and falls during breathing with the position of the tumor as revealed with the CyberKnife's image-guidance system. This allows Synchrony to guide the radiation beam so that it remains locked onto the moving tumor, thus allowing clinicians to significantly reduce treatment volumes and spare healthy tissue without the need for gating, breath holding, body frames or abdominal compression.

The treatment accuracy of the Synchrony system allows the margins necessary to account for uncertainty in target position to be narrow (at Erasmus MC, the total clinical error is routinely less than 1.5 mm), so that high SBRT doses can be delivered with relatively low toxicity to the central chest region. Keeping toxicity low is especially important for these patients, many of whom are treated with SBRT precisely because they are unable to withstand the rigors of surgery.

Study Details
The study found that tracking and correcting for respiratory motion with CyberKnife SBRT allowed clinicians to deliver treatment to the central lung with minimal toxicity, sparing surrounding healthy tissue, while also providing high levels of tumor control. In fact, the toxicity was among the lowest reported to date for central lung lesions.

Local tumor control was 91 percent for the entire group at one year and 76 percent for the entire group at two years. For the patients treated with at least 50 Gy, two-year local control was 85 percent. The overall two-year survival rate was 60 percent. The analysis of toxicity rates demonstrated that there were no serious complications (especially no life-threatening/disabling or fatal toxicities).

Historically, research has shown that even SBRT doses as low as 40 Gy can cause significant complications when treating lesions in the central chest. These findings point to the critical importance of careful treatment planning, accurate patient setup and precise radiation delivery.

For this study, the patients benefited from the team’s ability to use small error margins around the clinical target volume, with the CyberKnife system. The small margins could only be achieved with the Synchrony system.




Joost J. Nuyttens, M.D., Ph. D., did post-graduate medical specialty training including radiotherapy at the University of Ghent in Belgium and advanced radiation oncology training at the Medical University of South Carolina. He was a research fellow at the William Beaumont Hospital in Detroit. Since 2001, Nuyttens has been working as a radiation oncologist in the department of radiation oncology at Daniel Den Hoed Cancer Centre, Rotterdam, The Netherlands, with a special focus on thoracic, digestive and gynecologic cancers. For the past six years, he has been using CyberKnife robotic radiosurgery to treat early stage NSCLC and isolated lung metastases.?
References:?1 Brown WT, Wu X, Fayad F, et al. "Application of robotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent." Clin Oncol (R Coll Radiol) 2009;21:623-631; Vahdat S, Oermann EK, Collins SP, et al. "CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment." J Hematol Oncol 2010;3:6; van der Voort van Zyp NC, Prevost JB, Hoogeman MS, et al. "Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome." Radiother Oncol 2009;91:296-300; van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, et al. "Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer." Lung Cancer 2010;69:296-301
2 Timmerman R, McGarry R, Yiannoutsos C, et al. "Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer." J Clin Oncol 2006;24:4833-4839
3 Nuyttens JJ, van der Voort van Zyp NC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C, Pattynama PM, Hoogeman MS. "Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors." Radiother Oncol 2012, Mar;102(3):383-7

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...